Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy

Completed · Phase 1/Phase 2

Conditions studied: Facioscapulohumeral Muscular Dystrophy (FSHD)

In brief

The purpose of this study is to assess the safety and biological activity of ATYR1940 in participants with early onset FSHD.

Key facts

Study ID

NCT02603562

Run by

aTyr Pharma, Inc.

People needed

8

Starts

2016-03-30

Expected to finish

2016-12-12

Last updated by the study team

2023-10-19

Who can join

Age: 16 and older, up to 25. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Established, genetically confirmed diagnosis of FSHD.
• Onset of FSHD signs or symptoms prior to 10 years of age, as documented in the participant's medical record or based on participant or family report.
• Provide written informed consent or assent
• In the Investigator's opinion, participant is willing and able to complete all study procedures and comply with the weekly study visit schedule.

You may not qualify if…

• Currently receiving treatment with an immunomodulatory agent including targeted biological therapies within the 3 months before baseline; corticosteroids within 3 months before baseline; or high-dose non-steroidal anti-inflammatory agents within 2 weeks before baseline.
• Currently receiving curcumin or albuterol; use of a product that putatively enhances muscle growth or activity on a chronic basis within 4 weeks before baseline; statin treatment initiation or significant adjustment to statin regimen within 3 months before baseline (stable, chronic statin use is permissible).
• Use of an investigational product or device within 30 days before baseline.
• Evidence of an alternative diagnosis other than FSHD or a coexisting myopathy or dystrophy, based on prior muscle biopsy or other available investigations.
• History of severe restrictive or obstructive lung disease, or evidence for interstitial lung disease on screening chest radiograph.
• History of anti-synthetase syndrome, prior Jo-1 Ab-positivity, or a positive or equivocally positive Jo-1 Ab test result during screening.
• Chronic infection, such as hepatitis B, hepatitis C, or human immunodeficiency virus or a history of tuberculosis.
• Vaccination within 8 weeks before baseline or vaccination is planned during study participation.
• Symptomatic cardiomyopathy or severe cardiac arrhythmia, that may, in the Investigator's opinion, limit the participant's ability to complete the study protocol.
• Muscle biopsy within 30 days before baseline.

Where it is running

• Stanford University — Stanford, California, United States
• University of Iowa Children's Hospital — Iowa City, Iowa, United States
• OSU Wexner Medical Center — Columbus, Ohio, United States
• University of Utah — Salt Lake City, Utah, United States
• Centre d'nvestigation Clinique - Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques (CICCPCET) — Marseille, France
• Institut de Myologie — Paris, France
• Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta — Milan, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.